Research programme: virus-like particle vaccines - VBI Vaccines

Drug Profile

Research programme: virus-like particle vaccines - VBI Vaccines

Alternative Names: CMV eVLP - VBI; eVLP vaccines - VBI; HCV eVLP - VBI; Prophylactic respiratory syncytial virus vaccine - VBI Vaccines; RSV vaccine - VBI Vaccines; VBI-2501; VLP-based Cytomegalovirus - VBI; Zika virus eVLP vaccine - VBI Vaccines; Zika virus vaccine - VBI Vaccines

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VBI Vaccines
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Hepatitis C; Zika virus infection
  • Research Respiratory syncytial virus infections

Most Recent Events

  • 15 Aug 2017 VBI Vaccines plans a phase I/IIa trial for Glioblastoma (Recurrent, Second-line therapy or greater, Metastatic disease) in USA in the second half of 2017
  • 19 Jul 2016 Preclinical trials in Zika virus infection in USA (unspecified route) (Prevention)
  • 06 Nov 2015 VBI Vaccines plans a phase I trial for Cytomegalovirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top